In the present study, therefore, we have evaluated the guiding role of elevated pretreatment serum CEA levels for ACT receipt in stage IIA (T3N0M0) colon cancer using the large Surveillance, Epidemiology, and End Results (SEER) database. The gene discussed is CEACAM5; the disease is malignant colon neoplasm.